Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXS NASDAQ:CALT NASDAQ:CVAC NASDAQ:GPCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$6.37+0.9%$5.23$3.56▼$12.92$356.10M0.41355,599 shs23,474 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACVACCureVac$5.44+0.5%$4.73$2.37▼$5.72$1.22B2.53776,208 shs306,436 shsGPCRStructure Therapeutics$19.04-1.0%$22.14$13.22▼$47.48$1.09B-1.87832,152 shs198,864 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics-4.68%-1.56%+10.31%+58.54%-46.66%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+3.31%CVACCureVac-0.92%-0.18%-2.87%+69.06%+50.28%GPCRStructure Therapeutics-1.74%+2.61%-11.30%+3.78%-56.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXSAstria Therapeutics1.5983 of 5 stars3.61.00.00.01.61.70.0CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACVACCureVac4.7219 of 5 stars4.15.00.04.92.50.01.3GPCRStructure Therapeutics2.9038 of 5 stars3.53.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXSAstria Therapeutics 3.25Buy$30.00371.33% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACVACCureVac 2.20Hold$6.8325.73% UpsideGPCRStructure Therapeutics 3.00Buy$76.17300.06% UpsideCurrent Analyst Ratings BreakdownLatest ATXS, CVAC, CALT, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/13/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.005/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXSAstria TherapeuticsN/AN/AN/AN/A$3.97 per shareN/ACALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CVACCureVac$579.18M2.11$0.87 per share6.25$3.36 per share1.62GPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXSAstria Therapeutics-$94.26M-$1.87N/AN/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACVACCureVac$175.50M$0.925.91N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)Latest ATXS, CVAC, CALT, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CVACCureVac-$0.15N/AN/AN/A$4.27 millionN/A8/11/2025Q2 2025ATXSAstria Therapeutics-$0.61N/AN/AN/AN/AN/A5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXSAstria TherapeuticsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXSAstria TherapeuticsN/A17.3917.39CALTCalliditas Therapeutics AB (publ)9.442.692.59CVACCureVac0.057.657.64GPCRStructure TherapeuticsN/A23.2923.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXSAstria Therapeutics98.98%CALTCalliditas Therapeutics AB (publ)2.83%CVACCureVac17.26%GPCRStructure Therapeutics91.78%Insider OwnershipCompanyInsider OwnershipATXSAstria Therapeutics4.50%CALTCalliditas Therapeutics AB (publ)2.20%CVACCureVacN/AGPCRStructure Therapeutics9.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXSAstria Therapeutics3056.43 million53.89 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCVACCureVac880224.34 millionN/AOptionableGPCRStructure Therapeutics13657.34 million51.94 millionOptionableATXS, CVAC, CALT, and GPCR HeadlinesRecent News About These CompaniesPrincipal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)July 13 at 3:20 AM | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 7.3% - Here's WhyJuly 7, 2025 | marketbeat.comAnalysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) PT at $76.17July 6, 2025 | americanbankingnews.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's WhyJune 26, 2025 | marketbeat.comJefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PTJune 24, 2025 | msn.comStructure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% - Time to Buy?June 23, 2025 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)June 23, 2025 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)June 23, 2025 | marketbeat.comStructure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671June 20, 2025 | globenewswire.comStructure Therapeutics: Why Aleniglipron's Path To Market Remains TreacherousJune 10, 2025 | seekingalpha.comStructure Therapeutics Reports First Quarter 2025 Financial Results and Recent HighlightsMay 9, 2025 | finance.yahoo.comCitigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy RecommendationMay 3, 2025 | msn.comStructure draws new Buy at Citi on oral obesity drug pipelineMay 2, 2025 | msn.comViking among notable gainers as Pfizer raises deal prospectsApril 29, 2025 | msn.comIs Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?April 26, 2025 | msn.comH.C. Wainwright maintains buy on Structure Therapeutics sharesApril 24, 2025 | uk.investing.comResearchers crack the code of cell movementApril 24, 2025 | sciencedaily.comSEli Lilly jumps as results from weight-loss pill study rival competitor’sApril 17, 2025 | markets.businessinsider.comWhy did Lilly data for oral GLP-1 boost Structure and Metsera?April 17, 2025 | seekingalpha.comSA Asks: What's the best weight-loss drug stock right now?April 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATXS, CVAC, CALT, and GPCR Company DescriptionsAstria Therapeutics NASDAQ:ATXS$6.36 +0.06 (+0.87%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/14/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.CureVac NASDAQ:CVAC$5.44 +0.03 (+0.46%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Structure Therapeutics NASDAQ:GPCR$19.04 -0.19 (-0.99%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
